Substances that produce biologic responses within the body; they are synthesized by cells of the human body, animal cells, or microorganisms.
Second stage of drug testing that involves clinical phase trials.
Clinical phase trials
Testing of a new drug in selected patients.
Complementary and alternative therapies
Treatments considered outside the realm of conventional Western medicine.
General term for any substance capable of producing biologic responses in the body.
FDA's Critical Path Initiative
National strategy for transforming the way FDA-regulated products are developed, evaluated, manufactured, and used.
Food and Drug Administration (FDA)
U.S. agency responsible for the evaluation and approval of new drugs.
List of drugs and drug recipes commonly used by pharmacists.
Investigational New Drug Application (IND)
Application to the FDA that contains all the animal and cell testing data.
Drug after it has been administered.
Third stage of new drug evaluation by the FDA.
The study of medicines; the discipline pertaining to how drugs improve or maintain health.
Medical reference indicating standards of drug purity, strength, and directions for synthesis.
Treatment or prevention of disease by means of drugs.
Evaluation of a new drug after it has been approved and used in large numbers of patients.
Procedure implemented after a drug has been licensed for public use, designed to provide information on use and on occurrence of side effects
The branch of medicine concerned with the treatment of disease and suffering.